Observational studyMolecular genetics and metabolism2017
Hospitalizations for mitochondrial disease across the lifespan in the U.S.
Observational study in Molecular genetics and metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- A population-based cohort study of mitochondrial disease and mental health conditions in Ontario, Canada.Orphanet journal of rare diseases · 2025Article
- Preliminary investigation on the economic cost of mitochondrial disease in Chinese children.Orphanet journal of rare diseases · 2025Article
- The profound implications of mitochondrial myopathy on activities of daily living: an observational qualitative study of standardized structured and semi-structured patient interviews.Therapeutic advances in chronic disease · 2025Article
- Demographic characteristics, diagnostic challenges, treatment patterns, and caregiver burden of mitochondrial diseases: a retrospective cross-sectional study.Orphanet journal of rare diseases · 2024Article
- Clinical drivers of hospitalisation in patients with mitochondrial diseases.BMJ neurology open · 2024Article
- Epitope-level profiling in children with mitochondrial disease reveals limitations in the antibacterial antibody repertoire.Molecular genetics and metabolism · 2023Article
- Pathogenic BCS1L Mutation Resulting in Hypertrophic Cardiomyopathy: A Unique Presentation of Nuclear Mitochondrial Disease.Texas Heart Institute journal · 2023Article
- Estimation of the Number of Patients With Mitochondrial Diseases: A Descriptive Study Using a Nationwide Database in Japan.Journal of epidemiology · 2023Article
- Lactate metabolism is essential in early-onset mitochondrial myopathy.Science advances · 2023Article
- Early developmental delay in Leigh syndrome spectrum disorders is associated with poor clinical prognosis.Molecular genetics and metabolism · 2022Article
- Prevalence and health care costs of mitochondrial disease in Ontario, Canada: A population-based cohort study.PloS one · 2022Article
- Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Cardiovascular Outcomes in Patients With Mitochondrial Disease in the United States: A Propensity Score Analysis.Texas Heart Institute journal · 2021Article
- Susceptibility to COVID-19 in populations with health disparities: Posited involvement of mitochondrial disorder, socioeconomic stress, and pollutants.Journal of biochemical and molecular toxicology · 2021Review
- α-ketobutyrate links alterations in cystine metabolism to glucose oxidation in mtDNA mutant cells.Metabolic engineering · 2020Article
- A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008-2015.Orphanet journal of rare diseases · 2018Article
- Mitochondrial Disease in Children: The Nephrologist's Perspective.JIMD reports · 2018Article
- Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed.Molecular genetics and metabolism reports · 2017Article
- Progress and perspectives in primary mitochondrial myopathy: Highlights from the 2025 mitochondrial medicine masterclass with a focus on TK2 deficiency.Therapeutic advances in rare diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
importanceMitochondrial disease is being diagnosed with increasing frequency. Although children with mitochondrial disease often have severe, life-limiting illnesses, many survive into adulthood. There is, however, limited information about the impact of mitochondrial disease on healthcare utilization in the U.S. across the lifespan.
objectivesTo describe the characteristics of inpatient hospitalizations related to mitochondrial disease in the U.S., to identify patient-level clinical factors associated with in-hospital mortality, and to estimate the burden of hospitalizations on individual patients.
designCross-sectional and longitudinal observational studies.
settingU.S. hospitals.
participantsIndividuals with hospital discharges included in the triennial Healthcare Cost and Utilization Project (HCUP) Kids Inpatient Database (KID) and the National Inpatient Sample (NIS) in 2012 (cross-sectional analysis); individuals with hospital discharges included in the HCUP California State Inpatient Database from 2007 to 2011, inclusive (longitudinal analysis). EXPOSURE: Hospital discharge associated with a diagnosis of mitochondrial disease.
main outcome measuresTotal number and rate of hospitalizations for individuals with mitochondrial disease (International Classification of Diseases, 9th revision, Clinical Modification code 277.87, disorder of mitochondrial metabolism); in-hospital mortality.
resultsIn the 2012, there were approximately 3200 inpatient pediatric hospitalizations (1.9 per 100,000 population) and 2000 inpatient adult hospitalizations (0.8 per 100,000 population) for mitochondrial disease in the U.S., with associated direct medical costs of $113million. In-hospital mortality rates were 2.4% for children and 3.0% for adults, far exceeding population averages. Higher socioeconomic status was associated with both having a diagnosis of mitochondrial disease and with higher in-hospital mortality. From 2007 to 2011 in California, 495 individuals had at least one admission with a diagnosis of mitochondrial disease. Patients had a median of 1.1 hospitalizations (IQI, 0.6-2.2) per calendar year of follow-up; infants under 2y were hospitalized more frequently than other age groups. Over up to five years of follow up, 9.9% of participants with any hospitalization for mitochondrial disease were noted to have an in-hospital death. CONCLUSIONS AND RELEVANCE: Hospitalizations for pediatric and adult mitochondrial diseases are associated with serious illnesses, substantial costs, and significant patient time. Identification of opportunities to prevent or shorten such hospitalizations should be the focus of future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.